The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
Open accessAbstract
PKC isoforms tau, alpha, and beta play fundamental roles in the activation of T cells and other immune cell functions. Here we show that the PKC inhibitor AEB071 both abolishes the production of several cytokines by activated human T cells, keratinocytes, and macrophages in vitro and inhibits an acute allergic contact dermatitis response in rats. To translate these findings into humans, single and multiple ascending oral doses of AEB071 were administered to healthy volunteers and patients with psoriasis, respectively. AEB071 was well tolerated with no clinically relevant laboratory abnormalities. Ex vivo stimulation of lymphocytes from subjects exposed to single doses of AEB071 resulted in a dose-dependent inhibition of both lymphocyte proliferation and IL2 mRNA expression. Clinical severity of psoriasis was reduced up to 69% compared with baseline after 2 weeks of treatment, as measured by the Psoriasis Area Severity Index (PASI) score. The improvement in psoriasis patients was accompanied by histological improvement of skin lesions and may be partially explained by a substantial reduction of p40+ dermal cells, which are known to mediate psoriasis. These data suggest that AEB071 could be an effective novel treatment regimen for psoriasis and other autoimmune diseases, and that AEB071 warrants long-term studies to establish safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B. J., & DiGiovanni, J. (2005) · Nature Medicine · doi:10.1038/nm1162 · Cited by 752
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
Xia, Y.-P., Li, B., Hylton, D., Detmar, M., Yancopoulos, G. D., & Rudge, J. S. (2003) · Blood · doi:10.1182/blood-2002-12-3793 · Cited by 367
Cited by
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
NFAT pulls the strings during CD4+ T helper cell effector functions
Hermann-Kleiter, N., & Baier, G. (2010) · Blood · doi:10.1182/blood-2009-10-233585 · Cited by 218
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
He, X., Koenen, H. J. P. M., Smeets, R. L., Keijsers, R., van Rijssen, E., Koerber, A., van de Kerkhof, P. C., Boots, A. M. H., & Joosten, I. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.459 · Cited by 33
Metadata
- Authors
- Skvara, H., Dawid, M., Kleyn, E., Wolff, B., Meingassner, J. G., Knight, H., Dumortier, T., Kopp, T., Fallahi, N., Stary, G., Burkhart, C., Grenet, O., Wagner, J., Hijazi, Y., Morris, R. E., McGeown, C., Rordorf, C., Griffiths, C. E. M., Stingl, G., & Jung, T.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-09-02
- Volume
- 118
- Issue
- 9
- Pages
- 3151-3159
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2163279201
- Cited by
- 163
- References
- 3
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. https://app.cochat.ai/papers/10.1172/jci35636
- The paper
- Skvara, H., Dawid, M., Kleyn, E., Wolff, B., Meingassner, J. G., Knight, H., Dumortier, T., Kopp, T., Fallahi, N., Stary, G., Burkhart, C., Grenet, O., Wagner, J., Hijazi, Y., Morris, R. E., McGeown, C., Rordorf, C., Griffiths, C. E. M., Stingl, G., & Jung, T. (2008). The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. Journal of Clinical Investigation. https://doi.org/10.1172/jci35636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.